RESET PLATFORM
The Junevity RESET Platform develops novel therapeutics to restore gene networks with human disease data, machine learning and siRNA.
Transcriptional dysregulation drives disease
PROBLEM
Diseases related to longevity and aging see profound gene dysregulation, which is often overlooked in drug discovery due to its complexity.
Reset gene networks
SOLUTION
Dr. Janine Sengstack was the first to show that repressing a single transcription can reset gene expression to healthy state in her work at UCSF (PNAS, 2026), which opens up siRNA as a tool for reprogramming.
Junevity builds on this approach. We identify genetically-linked pathways that become overactive with age and disease. Then, we develop safe siRNA therapeutics to restore these pathways to a healthy state and reverse disease. siRNA enables infrequent dosing (1-2x/yr) with a strong safety profile (8 FDA approvals).
This approach unlocks new therapeutic space for age-related diseases and longevity.
RESET Platform
HOW WE DO IT
RESET is a therapeutic discovery platform combining human omics, genetic linkages, machine learning and siRNA.
Our first-of-its-kind platform enables safe siRNA therapeutics supported by genetic evidence.
